Published in
Elsevier, European Journal of Cancer, (157), p. 153-164, 2021
DOI: 10.1016/j.ejca.2021.07.029
Links
Tools
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Journal article published in 2021 by
Christelle de la Fouchardière 
,
Yann Godbert,
Cécile Dalban,
Frédéric Illouz,
Johanna Wassermann,
Christine Do Cao,
Stéphane Bardet ,
Slimane Zerdoud,
Cécile N. Chougnet ,
Mohamed Zalzali,
Danielle Benisvy,
Patricia Niccoli,
Laurence Digue,
Livia Lamartina ,
Paul Schwartz
and other authors.
,
Yann Godbert,
Cécile Dalban,
Frédéric Illouz,
Johanna Wassermann,
Christine Do Cao,
Stéphane Bardet ,
Slimane Zerdoud,
Cécile N. Chougnet ,
Mohamed Zalzali,
Danielle Benisvy,
Patricia Niccoli,
Laurence Digue,
Livia Lamartina ,
Paul Schwartz
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 